Research programme: Duchenne muscular dystrophy therapeutics - CombinatoRx
Alternative Names: DMD therapeutics - CombinatoRx/Charley's Fund/Nash Avery FoundationLatest Information Update: 22 Sep 2010
At a glance
- Originator CombinatoRx
- Developer Zalicus
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Muscular dystrophies
Most Recent Events
- 15 May 2009 Early research development is ongoing in USA
- 09 Nov 2007 Early research in Muscular dystrophy in USA (unspecified route)